SLENYTO NEWS

New German guidelines (AWMF) on autism therapy

New German guidelines (AWMF) on autism therapy were published in May 2021.
Slenyto is the recommended pharmacotherapy for children with ASD who failed sleep hygiene.

For the management of sleep disorders in ASD the guidelines recommend:
• Behavioral intervention is first-line
• If failed, melatonin should be initiated
• For children with ASD Slenyto is the recommended treatment with dosing up to a maximum of 10 mg

For more information click here.

NICE Guidelines for “Autism spectrum disorder in under 19s: support and management”

The NICE Guidelines for “Autism spectrum disorder in under 19s: support and management” have been updated in June 2021.

The updated guidance recommend that if a pharmacological intervention is needed to aid sleep, consider melatonin. (Interventions for sleep problems are described in pages 24-26, sections 1.7.4 to 1.7.8)

For more information click here.

POSITIVE OPINION BY HAS (THE HEALTH AUTHORITY IN FRANCE) FOR SLENYTO RTU IN CHILDREN WITH DEVELOPMENTAL DISORDERS AND NEUROGENETIC DISEASES

HAS published positive opinion for Slenyto RTU (temporary recommendation for use) for the treatment of sleep-wake rhythm disorders associated with Rett syndrome, Angelman syndrome or Bourneville’s tuberous sclerosis, in children (2 to 18 years old).

For more information click here and here.

 

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto (PedPRM) is now available in France!
    • Slenyto (PedPRM) is now available in Denmark!
    • Slenyto (PedPRM) is now also available in Iceland!
  • Partners

    Partners